In particular, mutations at V91 and N88 are present in molecules being developed to treat autoimmune disease through selective IL-2 signaling in Treg cells (Peterson et al., 2018, Ghelani et al., 2020, Gavin et al., 2017). Here, IL2 is linked to autoimmune disease.